recent posts

banner image

Cadila Healthcare Advances after USFDA nod for oral Suspension Drug

For more Live premium stock future Visit Us:-http://ripplesadvisory.com/premium-stock-future-.php or Get Free Trials Just Call @96-44-40-50-56.

Cadila Healthcare was up 1.26% to Rs 459.05 at 10:22 IST on BSE after the company said it has received final US drug regulator nod for an oral suspension drug.

The announcement was made after market hours yesterday, 26 April 2017.

Meanwhile, the S&P BSE Sensex was down 49.17 points or 0.16% at 30,084.18.

On the BSE, 26,000 shares were traded on the counter so far as against the average daily volumes of 1.40 lakh shares in the past one-quarter. The stock had hit a high of Rs 463.25 and a low of Rs 457.55 so far during the day.

The stock had hit a record high of Rs 466.10 on 7 April 2017 and a 52-week low of Rs 305.05 on 24 June 2016. It had underperformed the market over the past one month till 26 April 2017, advancing 1.6% compared with the Sensex's 2.42% rise. The scrip had, however, outperformed the market over the past one-quarter, gaining 26.72% as against the Sensex's 8.75% rise.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Rs 1.


Cadila Healthcare Advances after USFDA nod for oral Suspension Drug Cadila Healthcare Advances after USFDA nod for oral Suspension Drug Reviewed by Ripples Advisory Private Limited on April 27, 2017 Rating: 5

No comments:

Note: only a member of this blog may post a comment.

Stay Connected

Powered by Blogger.